Avalyn Pharma (NASDAQ:AVLN) Stock Falls 8.1% After Analyst Downgrade

Avalyn Pharma Inc. (NASDAQ:AVLN – Get Free Report) shares were down 8.1% during trading on Tuesday after Morgan Stanley lowered their price target on the stock from $57.00 to $53.00. Morgan Stanley currently has an overweight rating on the stock. Avalyn Pharma traded as low as $27.04 and last traded at $27.36. Approximately 28,822 shares traded hands during mid-day trading, a decline of 92% from the average daily volume of 340,475 shares. The stock had previously closed at $29.76.

Other research analysts have also issued reports about the company. Weiss Ratings reiterated a “sell (d+)” rating on shares of Avalyn Pharma in a report on Wednesday, November 11th. Raymond James Financial initiated coverage on Avalyn Pharma in a research note on Friday, October 2nd. They issued an “outperform” rating and a $60.00 target price for the company. Finally, Wall Street Zen upgraded Avalyn Pharma from a “sell” rating to a “hold” rating in a report on Saturday, November 14th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $59.20.

Read Our Latest Stock Analysis on Avalyn Pharma

Insider Buying and Selling

In other Avalyn Pharma news, insider Fmr Llc sold 53,454 shares of Avalyn Pharma stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $30.21, for a total value of $1,614,845.34. Following the transaction, the insider owned 2,056,081 shares of the company’s stock, valued at approximately $62,114,207.01. The trade was a 2.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Institutional Investors Weigh In On Avalyn Pharma

Large investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Avalyn Pharma during the third quarter worth $29,000. Manchester Capital Management LLC bought a new stake in Avalyn Pharma in the 3rd quarter valued at $36,000. Algert Global LLC bought a new stake in Avalyn Pharma in the 3rd quarter valued at $465,000. Profund Advisors LLC acquired a new position in Avalyn Pharma in the 3rd quarter worth $668,000. Finally, Bank of New York Mellon Corp acquired a new position in Avalyn Pharma in the 2nd quarter worth $1,321,000.

Avalyn Pharma Price Performance

The business has a 50 day simple moving average of $28.15. The company has a current ratio of 25.76, a quick ratio of 25.76 and a debt-to-equity ratio of 0.04.

Avalyn Pharma (NASDAQ:AVLN – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.03). Analysts predict that Avalyn Pharma Inc. will post -3.87 earnings per share for the current year.

Avalyn Pharma Company Profile

(Get Free Report)

Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled treatments for pulmonary fibrosis, including idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. Its approach is designed to deliver medicine directly to the lungs. The company’s pipeline includes AP01, an investigational inhaled formulation of pirfenidone, and AP02, an investigational inhaled formulation of nintedanib. Both medicines are based on drugs used in oral form for pulmonary fibrosis, but Avalyn’s inhaled candidates are being studied as potential alternatives to oral treatment.

Further Reading

Receive News & Ratings for Avalyn Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalyn Pharma and related companies with MarketBeat.com's FREE daily email newsletter.